Ann: DFU Clinical Trial Enrolment Complete, page-4

It's possible Phase II will be designed and enrollment begun prior to year end.

Taking this momentum into account, with an accompanying sp re-rate higher, a PP (if needed) to pay for Phase II would be another welcome entry point for me.

The study's endpoints, in my mind, are easily established and measured. First, don't kill the patient. Second, measure the DFU before treatment, then after. Third, once efficacy proven, repeat on a larger scale. Fourth, commercialize.

Fundamentals like funding, JVs, T/Os, competition, even inrigue may swirl around CYP... I think it will be a good ride... (Hint: 87.6% v 51.1 wound reduction CYP v control))

OV
***
*****